Search Results

You searched for : Nintedanib

	Glenmark Pharmaceuticals receives ANDA tentative approval for Nintedanib Capsules, 100 mg and 150 mg According to IQVIATM sales data for the 12 month period ending April 2021, the Ofev Capsules, 100 mg and 150 mg market achieved annual sales ... Jun 25
	New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1 New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1... Nov 07
	Cipla launches Nintib to treat Idiopathic Pulmonary Fibrosis, in continuation of its fight against rare lung diseases Cipla Limited today announced that it has launched generic Nintedanib for the treatment of Idiopathic Pulmonary Fibrosis ... Oct 21
	Glenmark introduces a generic version of NINDANIB for the treatment of Pulmonary Fibrosis Glenmark being a leader in the area of respiratory has been amongst the first to launch the branded generic version for the treatment of Pulmonary ... Oct 14
	Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease European Medicines Agency (EMA) has adopted a positive opinion recommending granting marketing authorisation for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (... Mar 03
	INBUILDÂ® meets primary endpoint - study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases1 New data showed positive effect of nintedanib on slowing decline of lung function in a broad range of fibrosing interstitial lung diseases with a progressive ... Oct 01
6 Matching result(s) found!

-Advertisements-

Trending Now
	Dish TV Revolutionizes Entertainment with ‘Dish TV Smart+’ Services, Offering TV and OTT on Any Screen, AnywhereApril 26, 2024
	Arohan Financial Services Recognized Among India's Best Workplaces in BFSI 2024April 26, 2024
	Why Podcasts Are the Next Big Thing in Healthcare Advertising in IndiaApril 26, 2024
	Challenges of Child Growth at High Altitudes: New Study Reveals ImpactApril 26, 2024
	Staying Cool in India's Scorching Heat: Heatwave Safety TipsApril 26, 2024
	The Dark Side of Neotame (Artificial Sweetener): New Research Raises Concerns about Gut HealthApril 26, 2024
	Sightsavers India Fellowship Program Invites Applications for Promising OphthalmologistsApril 25, 2024
	Transforming Brain Healthcare: India's Visionary Task Force for Neurological DisordersApril 25, 2024
	The Battle Against Malaria: Rising Trends and Vaccine InnovationsApril 25, 2024
	Talc and Asbestos Controversy: Inside Johnson & Johnson's Courtroom StruggleApril 25, 2024
	The Hidden Struggles of Parenthood: Addressing Isolation, Loneliness, and BurnoutApril 25, 2024
	FDA Confirms Bird Flu Virus Remnants in Pasteurized Milk: Safety and Regulatory InsightsApril 24, 2024
	Sarvodaya Hospital Redefines Total Knee Replacement Surgery with Augmented Reality April 23, 2024
	Fateh Education announces partnership to expand educational opportunities for Indian studentsApril 23, 2024
	10 Strategies to counter disinformation for the healthcare digital ecosystemApril 23, 2024
	Is Selling Over-the-Counter (OTC) Drugs in General Stores A Step Towards Affordable Healthcare in IndiaApril 23, 2024
	Student Health Crisis: Food Poisoning Incident Strikes Pune Coaching CentreApril 23, 2024
	The Impact of Diabetes on Kidney Health: Diabetic Nephropathy ExplainedApril 23, 2024
	Toddler Hospitalized After Consuming Expired Chocolates: Health Concerns RaisedApril 23, 2024
	After months of diagnostic delay, a migrant worker could access TB services only when a community health worker met himApril 22, 2024

Search Results

Glenmark Pharmaceuticals receives ANDA tentative approval for Nintedanib Capsules, 100 mg and 150 mg

New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1

Cipla launches Nintib to treat Idiopathic Pulmonary Fibrosis, in continuation of its fight against rare lung diseases

Glenmark introduces a generic version of NINDANIB for the treatment of Pulmonary Fibrosis

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease

INBUILDÂ® meets primary endpoint - study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases1

Trending Now